NCT02556632View on ClinicalTrials.gov

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Breast CarcinomaPainRadiation-Induced DermatitisStage 0 Breast Cancer
Interventions
DRUG

Curcumin-based Gel

Applied topically

PROCEDURE

Dermatologic Complications Management

Apply HPR Plus topically

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Apply placebo gel topically

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (6)

14642

University of Rochester, Rochester

19713

Delaware/Christiana Care NCORP, Newark

43215

Columbus NCORP, Columbus

45420

Dayton Oncology Research Program, Dayton

55426

Metro-Minnesota NCORP, Minneapolis

62526

Heartland NCORP, Decatur

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gary Morrow

OTHER

NCT02556632 - Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer | Biotech Hunter | Biotech Hunter